SGMT Earnings — Sagimet Biosciences Inc. Series A Common Stock Post-ER Performance | BigEarnings
SGMT — Sagimet Biosciences Inc. Series A Common Stock
XNAS · Healthcare · Biotechnology
Price$7.34
Market Cap$445.8M
P/E—
52W Range$3.32 – $11.41
Next Earnings2026-08-12
About Sagimet Biosciences Inc. Series A Common Stock
Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.
